2002-82-6

Basic information

• Product Name: 4-FLUORO-3-AMINO-ACETOPHENONE
• Synonyms: 4-FLUORO-3-AMINO-ACETOPHENONE;3'-amino-4'-fluoroacetophenone;3-Amino-4-fluoroacetophenone/3-amino-4'-fluoroacetophenone;4'-fluoro-3'-aminoacetophenone,1-(3-amino-4-fluorophenyl)ethanone;3'-Amino-4'-fluoroacetophenone;1-(3-amino-4-fluorophenyl)ethanone;4-Acetyl-2-aminofluorobenzene;1-(3-aMino-4-fluorophenyl)ethan-1-one
• CAS NO: 2002-82-6
• Molecular Formula: C₈H₈FNO
• Molecular Weight: 153.15
• Product Categories: Acetophenone series
• Mol File: 2002-82-6.mol

Chemical Properties

• Melting Point: 70-72℃
• Boiling Point: 290℃
• Flash Point: 129℃
• Appearance: /
• Density: 1.201
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 2.02±0.10(Predicted)
• CAS DataBase Reference: 4-FLUORO-3-AMINO-ACETOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORO-3-AMINO-ACETOPHENONE(2002-82-6)
• EPA Substance Registry System: 4-FLUORO-3-AMINO-ACETOPHENONE(2002-82-6)

Safety Data

• Hazardous Substances Data: 2002-82-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Fluoro-3-amino-acetophenone is utilized as a key intermediate in the synthesis of pharmaceuticals. Its unique structure and reactivity make it a valuable building block for the development of new drugs and medicinal compounds. The presence of the fluorine atom can significantly influence the pharmacokinetic and pharmacodynamic properties of the final drug product, potentially enhancing its efficacy and safety profile.
Used in Organic Synthesis:
In the field of organic chemistry, 4-Fluoro-3-amino-acetophenone serves as a versatile starting material for the synthesis of a wide range of chemical products. Its reactivity and structural features allow for various chemical reactions, such as substitution, addition, and rearrangement, to be performed, leading to the formation of complex molecules with potential applications in different industries.
Used in Chemical Research:
4-Fluoro-3-amino-acetophenone is also employed in academic and industrial research settings as a model compound for studying the effects of fluorination and amino substitution on the chemical and physical properties of molecules. This knowledge can be applied to the design of new materials and compounds with tailored properties for specific applications.
As with many chemicals, it is essential to handle and store 4-Fluoro-3-amino-acetophenone with care to minimize the risks associated with its reactivity and potential hazards. Proper safety measures and protocols should be followed to ensure the safe use of 4-FLUORO-3-AMINO-ACETOPHENONE in various applications.

Upstream product

• 400-93-1 3-nitro-4-fluoroacetophenone 
• 403-42-9 1-(4-fluorophenyl)ethanone 

Downstream Products

• 701-42-8 Methyl-(4-fluor-3-amino-phenyl)-carbinol 
• 1181772-21-3 3'-chlorosulfonyl-4'-fluoroacetophenone 
• 1297551-07-5 ethyl erythro-3-(3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}-4-fluoro-phenyl)-2-methylbutanoate 

Relevant articles and documents

Defect-mediated selective hydrogenation of nitroarenes on nanostructured WS2

Transition metal dichalcogenides (TMDs) are well known catalysts as both bulk and nanoscale materials. Two-dimensional (2-D) TMDs, which contain single- and few-layer nanosheets, are increasingly studied as catalytic materials because of their unique thickness-dependent properties and high surface areas. Here, colloidal 2H-WS2 nanostructures are used as a model 2-D TMD system to understand how high catalytic activity and selectivity can be achieved for useful organic transformations. Free-standing, colloidal 2H-WS2 nanostructures containing few-layer nanosheets are shown to catalyze the selective hydrogenation of a broad scope of substituted nitroarenes to their corresponding aniline derivatives in the presence of other reducible functional groups. Microscopic and computational studies reveal the important roles of sulfur vacancy-rich basal planes and tungsten-terminated edges, which are more abundant in nanostructured 2-D materials than in their bulk counterparts, in enabling the functional group selectivity. At tungsten-terminated edges and on regions of the basal planes having high concentrations of sulfur vacancies, vertical adsorption of the nitroarene is favored, thus facilitating hydrogen transfer exclusively to the nitro group due to geometric effects. At lower sulfur vacancy concentrations on the basal planes, parallel adsorption of the nitroarene is favored, and the nitro group is selectively hydrogenated due to a lower kinetic barrier. These mechanistic insights reveal how the various defect structures and configurations on 2-D TMD nanostructures facilitate functional group selectivity through distinct mechanisms that depend upon the adsorption geometry, which may have important implications for the design of new and enhanced 2-D catalytic materials across a potentially broad scope of reactions.

Bulk iron pyrite as a catalyst for the selective hydrogenation of nitroarenes

Bulk iron pyrite (FeS2) functions as an inexpensive, Earth-abundant, off-the-shelf catalyst capable of selectively hydrogenating a broad scope of substituted nitroarenes to their corresponding aniline derivatives using molecular hydrogen.

BICYCLIC COMPOUND

Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

Highly selective transfer hydrogenation of functionalised nitroarenes using cobalt-based nanocatalysts

Anilines are important feedstock for the synthesis of a variety of chemicals such as dyes, pigments, pharmaceuticals and agrochemicals. The chemoselective catalytic reduction of nitro compounds represents the most important and prevalent process for the manufacture of functionalized anilines. Consequently, the development of selective catalysts for the reduction of nitro compounds in the presence of other reducible groups is a major challenge and is crucial. In this regard, herein we show that the cobalt oxide (Co3O4-NGr@C) based nano-materials, prepared by the pyrolysis of cobalt-phenanthroline complexes on carbon constitute highly selective catalysts for the transfer hydrogenation of nitroarenes to anilines using formic acid as a hydrogen source. Applying these catalysts, a series of structurally diverse and functionalized nitroarenes have been reduced to anilines with unprecedented chemo-selectivity tolerating halides, olefins, aldehyde, ketone, ester, amide and nitrile functionalities.

Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization

The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by crystal structure analysis, we reversed the sulfonamide group and identified a new binding mode. A structure-activity relationship study on this new series led to several potent BRD4 inhibitors with IC50 of about 0.05-0.1 μM in FP binding assay and GI50 of 0.1-0.3 μM in cell based assays. To complete the lead-like assessment of this series, we further checked its effects on BRD4 downstream protein c-Myc, investigated its selectivity among five different bromodomain proteins, as well as the metabolic stability test, and reinforced the utility of 2-thiazolidinone scaffold as BET bromodomain inhibitors in novel anticancer drug development.

Nitrogen-doped graphene-activated iron-oxide-based nanocatalysts for selective transfer hydrogenation of nitroarenes

Nanoscaled iron oxides on carbon were modified with nitrogen-doped graphene (NGr) and found to be excellent catalysts for the chemoselective transfer hydrogenation of nitroarenes to anilines. Under standard reaction conditions, a variety of functionalized and structurally diverse anilines, which serve as key building blocks and central intermediates for fine and bulk chemicals, were synthesized in good to excellent yields.

Nanoscale Fe2O3-based catalysts for selective hydrogenation of nitroarenes to anilines

Production of anilines - key intermediates for the fine chemical, agrochemical, and pharmaceutical industries - relies on precious metal catalysts that selectively hydrogenate aryl nitro groups in the presence of other easily reducible functionalities. Herein, we report convenient and stable iron oxide (Fe2O3) - based catalysts as a more earth-abundant alternative for this transformation. Pyrolysis of iron-phenanthroline complexes on carbon furnishes a unique structure in which the active Fe2O 3 particles are surrounded by a nitrogen-doped carbon layer. Highly selective hydrogenation of numerous structurally diverse nitroarenes (more than 80 examples) proceeded in good to excellent yield under industrially viable conditions.

SUBSTITUTED 3-PHENYLPROPIONIC ACIDS AND THE USE THEREOF

The present application relates to novel 3-phenylpropionic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.

PHOSPHODIESTERASE 10 INHIBITORS

The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.